Fourth, study of potential mechanisms of primary resistance to pemigatinib revealed that baseline co-alterations in tumor suppressors, particularly TP53 and ARID1A, and oncogenic co-alterations in the MAPK pathway were associated with shorter PFS compared to those without alterations. Here, TP53 is linked to neoplasm.